Managing vascular occlusion after HA filler: the CMAC algorithm

|Longeva Pharmacy Clinical Team
A clear vial beside a countdown timer on a steel tray

The clinical question is not whether a vascular event will ever happen in a busy clinic, but how the first hour of management will look.

Vascular occlusion following hyaluronic acid (HA) filler injection is the most time-critical complication in aesthetic medicine. The window between occlusion and irreversible tissue necrosis is narrow, measured in minutes to hours depending on the vessel affected and the collateral supply available. Despite this, surveys consistently show that a significant proportion of practitioners have not drilled a formal protocol and are uncertain about hyaluronidase dosing when the moment arrives.

This article summarises the CMAC (Complications in Medical Aesthetic Clinics) algorithm for vascular occlusion management as published in the JCAD CMAC Guideline on HA Filler-induced Vascular Occlusion. It is written for licensed UK aesthetic practitioners as a desk-side aide-memoire. It does not replace the full guideline, individual clinical training, or the judgement of a supervising clinician. Where dosing figures are referenced below, they are drawn from the CMAC and ACE Group guidance documents and attributed accordingly.

What is vascular occlusion and why does it happen?

Vascular occlusion occurs when injected filler material either enters a blood vessel directly (intravascular injection) or compresses a vessel externally, impeding flow. Both mechanisms can reduce or halt perfusion to the dependent tissue. The consequences range from localised ischaemia to skin necrosis and, in the worst cases, blindness or stroke when retrograde embolisation reaches the ophthalmic or cerebral circulation.

The face is supplied by a dense, anastomosing vascular network. The danger zones most cited in the literature include the glabella (supratrochlear and supraorbital arteries), the nasolabial fold, the nasal tip (lateral nasal artery), the temples, and the lips. The precise anatomy varies significantly between individuals, which is why no single injection point can be declared safe from all vascular risk.

HA fillers carry occlusion risk because hyaluronic acid particles are large enough to obstruct small-calibre arteries and arterioles. The rheological properties of different HA products influence the particle size and therefore the embolic potential, though no HA product is exempt from this risk.

Recognition: immediate and delayed signs

Early recognition is the single most important factor determining outcome. Practitioners should be alert to two categories of signs.

Immediate signs (occurring during or within seconds of injection):

  • Sudden, severe pain disproportionate to the procedure
  • Blanching of the skin in a distribution consistent with vascular territory (not simple bruising)
  • Skin colour change to a dusky grey or white, particularly tracking beyond the needle tip
  • Patient reporting visual disturbance, blurring, or sudden vision loss

Delayed signs (minutes to hours post-injection):

  • Violaceous or mottled skin discolouration consistent with livedo reticularis
  • Prolonged capillary refill time (more than two seconds in affected tissue)
  • Tissue oedema localised to the ischaemic zone
  • Vesicle formation in more advanced ischaemia
  • Pain returning or worsening after initial improvement

The peer-reviewed literature (PMC8211329) documents that delayed presentations are often underestimated in severity because the practitioner and patient both assume initial pallor is vasospasm. This misattribution causes harmful delays. Treat blanching in a vascular distribution as an occlusion until proven otherwise.

Preparation and having a crash protocol in place

No management algorithm is useful if the equipment and medication are not immediately accessible. Before any HA filler treatment session, the following should be confirmed present and in date:

  • Hyaluronidase (sufficient stock for high-dose intervention), drawn and ready or reconstituted per the clinic's standard operating procedure
  • Emergency contact numbers for the nearest A&E department and ophthalmology on-call
  • A written, printed vascular occlusion SOP visible in every treatment room
  • A trained second person available or contactable

The ACE Group UK vascular occlusion guidance emphasises that preparation is not optional: a practitioner who must locate or reconstitute hyaluronidase under the stress of an active occlusion event will lose critical minutes. Stock management and pre-session readiness checks should be built into clinic procedure.

Longeva Pharmacy's dermal filler collection and full product catalogue include hyaluronidase and associated emergency products; practitioners without a current supply should ensure availability before any filler session.

The CMAC algorithm: an overview

The CMAC algorithm, published in the JCAD CMAC guideline, provides a stepwise framework for managing suspected HA filler-induced vascular occlusion. The algorithm is structured around a decision tree based on the clinical presentation and the anatomical zone affected. The steps below are a simplified summary; practitioners must read and follow the full guideline.

  1. Stop injection immediately. Withdraw the needle or cannula without additional tissue manipulation.
  2. Confirm suspected occlusion. Assess skin colour, pain, blanching distribution, and capillary refill. If intravascular injection into an ophthalmic vessel is suspected, treat this as an ophthalmic emergency and dial 999 or 112 immediately while beginning hyaluronidase administration.
  3. Administer hyaluronidase without delay. The CMAC guideline endorses a high-dose pulsed approach. The exact dosing protocol is specified in the full guideline and depends on the anatomical zone and clinical response; do not rely on this summary for specific unit numbers. Aspirate per your training where feasible. Massage the area gently to aid dispersion.
  4. Reassess perfusion at defined intervals. Capillary refill, skin colour, and pain should be monitored after each dose administration. If improvement is not seen within the timeframe described in the guideline, repeat dosing is indicated.
  5. Escalate if no improvement. Failure to restore perfusion within the algorithm's defined response window is an indication for emergency referral. Document all interventions.

The CMAC algorithm is also cross-referenced with the PMC8570661 systematic review, which synthesises case series and expert consensus on vascular occlusion management and supports the rationale for early, high-dose hyaluronidase intervention.

Hyaluronidase use: principles and dosing guidance

Hyaluronidase is the definitive reversal agent for HA filler-induced vascular occlusion. It enzymatically degrades the hyaluronic acid matrix, restoring vessel patency. The following are principles drawn from the CMAC guideline and the JCAD safe use of hyaluronidase guideline. They are not a substitute for reading those documents in full or for completing recognised training in vascular occlusion management.

High-dose pulsed approach. Both the CMAC and ACE Group guidelines support a high-dose pulsed administration strategy rather than low-dose conservative dosing. The rationale is that insufficient hyaluronidase is a more dangerous error than a dose that exceeds the minimum effective amount. Specific dosing figures are stated in the full CMAC guideline and the ACE Group document; practitioners should follow those numbers as trained, not this article's summary.

Reconstitution and dilution. The JCAD hyaluronidase guideline sets out reconstitution standards. Use a diluent and concentration consistent with your training and the relevant SPC. Correct reconstitution affects both efficacy and safety.

Route and distribution. Hyaluronidase should be injected into the affected zone, tracking the suspected vascular distribution. The CMAC guideline describes injection technique in relation to anatomical zone; this is where specific technique training is indispensable.

Allergy consideration. Hyaluronidase carries a risk of hypersensitivity. In an occlusion emergency, the risk-benefit balance firmly favours administration, but practitioners should be aware of this and have adrenaline available for anaphylaxis management.

Continued reassessment. Response to hyaluronidase is not always immediate. The ACE Group guidance and CMAC algorithm both specify reassessment intervals. Failure to respond is not a reason to stop; it is an indicator for repeat dosing and parallel escalation.

Escalation: when to refer and what to say

Not every occlusion will resolve in-clinic. The following presentations require immediate emergency escalation regardless of initial hyaluronidase administration:

  • Any visual symptoms: blurring, loss of vision in one or both eyes, diplopia, or ptosis. These may indicate ophthalmic artery compromise. Call 999 immediately and state suspected intravascular filler injection with ophthalmic involvement.
  • Neurological symptoms: altered consciousness, facial drooping, dysarthria, limb weakness. Treat as suspected stroke and activate the emergency pathway.
  • No return of perfusion after two or more full rounds of hyaluronidase per the guideline protocol. The tissue ischaemia window is closing; do not delay referral waiting for a third or fourth assessment.
  • Skin blistering or black discolouration indicating established necrosis. Even if the acute occlusion phase has passed, specialist wound management is required.

When calling for emergency assistance, use clear language: state that you have a patient with suspected vascular occlusion following hyaluronic acid filler injection, that you have administered hyaluronidase, and describe the current clinical signs. Avoid euphemism. Emergency teams respond better to direct clinical language.

The BCAM dermal fillers guidance provides additional context on the escalation and governance framework for practitioners registered with a professional body.

Prevention: aspiration, cannula versus needle, and anatomy

Vascular occlusion cannot be eliminated entirely, but individual technique choices affect risk. The following points summarise current consensus, noting that the evidence base continues to evolve.

Aspiration. The aspiration debate is ongoing. Some guidelines recommend aspiration before injection as a check for intravascular placement, while others note that negative aspiration provides false reassurance because small arteries collapse under the negative pressure of aspiration and may not return blood even when the needle is intravascular. The CMAC guideline does not recommend aspiration as a reliable primary safety measure; it recommends a combination of slow injection, low volume per pass, and anatomical awareness. Aspiration is not harmful if performed, but it should not replace other precautions.

Cannula versus needle. Blunt-tip cannulas are associated with a lower but not absent vascular occlusion risk compared with sharp needles, particularly in higher-risk anatomical zones. The mechanism of greater safety is the blunt tip's tendency to displace rather than pierce vessel walls. However, cannulas can still enter vessels, particularly at entry points or where vessels are under tension. Cannula use in appropriate zones is a risk reduction measure, not a risk elimination measure.

Anatomical knowledge. Detailed knowledge of facial vascular anatomy, including expected variation, remains the most important technical risk-reduction factor. Practitioners should undertake ongoing cadaveric or ultrasound anatomy training. High-resolution ultrasound for vascular mapping before injection in high-risk zones is gaining support in the literature, though it is not yet standard practice in most UK clinics.

Documentation and Yellow Card reporting

Every vascular occlusion event, including those that resolve fully in-clinic, requires formal documentation. The record should include:

  • Product used (lot number, volume, injection sites)
  • Time of onset of symptoms and time of first hyaluronidase administration
  • Doses of hyaluronidase administered, including volumes, concentrations, and intervals
  • Clinical response at each reassessment
  • Any referral made, and the outcome communicated back from the receiving clinician
  • Follow-up plan and patient-facing information provided

Yellow Card reporting to the MHRA is mandatory for any serious adverse event involving a licensed medicine and strongly recommended for medical device-related complications. HA fillers that hold a CE or UKCA mark as medical devices should be reported via the MHRA's device reporting route. Reporting is not an admission of liability; it is a professional obligation and contributes to post-market safety surveillance. The MHRA Yellow Card portal is accessible at yellowcard.mhra.gov.uk.

Practitioners registered with the GPhC, GMC, NMC, or GDC are also expected to act in line with their professional body's duty of candour requirements. Where a patient has suffered harm, this includes honest communication and appropriate referral for follow-up care.

If you are not yet registered with Longeva Pharmacy's practitioner programme, you can register here to access our full clinical product range and practitioner support resources.

Key takeaways

  • Vascular occlusion is a time-critical emergency. Blanching in a vascular distribution should be treated as occlusion until proven otherwise, not assumed to be vasospasm.
  • Hyaluronidase must be immediately available before every HA filler session, not sourced reactively during an event.
  • The CMAC algorithm provides a validated stepwise framework. Read the full guideline; do not rely on any summary, including this one, for specific dosing numbers.
  • High-dose pulsed hyaluronidase, as outlined in the CMAC and ACE Group guidance, is supported by the available consensus. Underdosing is a more dangerous error than appropriate dosing.
  • Visual or neurological symptoms require immediate 999 activation alongside hyaluronidase administration, not instead of it.
  • Aspiration reduces but does not eliminate intravascular injection risk. Cannula use reduces but does not eliminate vascular occlusion risk. Anatomical knowledge is the primary safeguard.
  • Every event must be documented in full and reported via Yellow Card where applicable.

References

Reviewed for clinical accuracy under the supervision of our Superintendent Pharmacist, Alicia Barker (GPhC 2241860). Longeva Pharmacy is a GPhC-registered pharmacy (registration 9012378) operating under MHRA WDA(H) licence 59619. Information is intended for licensed UK practitioners and does not replace individual clinical judgement.